Progress Software Corp (PRGS US, +N, 24-Jul-25) On July 23rd, Yogesh Gupta (Chief Executive Officer since Oct 2016) bought $103,200 worth of stock on July 23rd at $ 49.14, and David Krall (Non-Executive since Jan 2008) spent $251,000 at $48.90. For Gupta it is only his second purchase. In October 2020 he spent a similar amount at $37, which proved timely. Krall […]
CRISPR Therapeutics AG (CRSP US, +N, 18-Jul-25) Simeon George (Non-Executive since April 2015) purchased 989,812 shares, spending $51.5 million on July 16th at $52.03, more than doubling his position. The purchase is made indirectly on behalf of SR One Capital Management, a transatlantic biotech venture capital firm where he serves as Managing Partner (joined 2007). SR One was previously […]
Welltower Inc (WELL US, +1, 03-Jul-25) Andrew Gundlach (Director since July 2024) purchased just over $3 million worth of stock on June 30th at $151.46, his first investment since joining. While his tenure is still short, the size and timing of the purchase—near the stock’s all-time high—make it noteworthy. The company requires non-executive directors to hold at least 5x […]
PVH Corp (PVH US, +1, 01-Jul-25) Stefan Larsson (CEO since 2021, joined 2019) purchased $1 million worth of stock on June 26th at $63.92, increasing his stake by 6%. This marks only his 2nd purchase despite a reasonable tenure with the company. He made a similar-sized purchase in September 2022 at $53.94, which proved to be very well-timed. It’s […]
Vera Therapeutics Inc (VERA US, +N, 26-Jun-25) Patrick Enright (Non-Executive since 2020) bought $ 5.3 million of stock on 24th June at $ 21.11, increasing his stake by 5%. The purchases were indirect and on behalf of Longitude Capital, where he is co-founder and Managing Director. The purchase takes their stake to 8.5%. While he has made 3 subscriptions […]